Avastin

Roche gets European approval for Tecentriq combo vs. lung cancer
Roche gets European approval for Tecentriq combo vs. lung cancer
Reuters
Roche
Europe
Tecentriq
Avastin
lung cancer
metastatic non-squamous non-small cell lung cancer
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
BioSpace
Genentech
FDA
Tecentriq
Avastin
non-squamous cell non-small cell lung cancer
Flag link:
One more shot at slowing Keytruda’s first-line lung cancer domination
One more shot at slowing Keytruda’s first-line lung cancer domination
EP Vantage
Keytruda
Merck
Roche
Tecentriq
Avastin
lung cancer
Flag link:
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Pharmaforum
UK
Roche
Avastin
wet age-related macular degeneration
Novartis
Bayer
Flag link:
In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
Endpoints
Genentech
Roch
Tecentriq
Avastin
lung cancer
FDA
Flag link:
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Fierce Pharma
Roche
Avastin
Tecentriq
lung cancer
Flag link:
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
S&P Global
AbbVie
Roche
Humira
Rituxan
Herceptin
Avastin
Flag link:
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Endpoints
clinical trials
VBL Therapeutics
VB-111
Roche
Avastin
glioblastoma
Flag link:
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Fierce Pharma
Roche
Pharma CEOs
Severin Schwan
biosimilars
Herceptin
Rituxan
Avastin
Flag link:
The 2018 biosimilar litigation landscape: A primer
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
Flag link:
Roche's Fight With Pfizer May Be Just The Beginning
Roche's Fight With Pfizer May Be Just The Beginning
Forbes
Roche
Pfizer
Herceptin
biosimilars
cancer
Avastin
Rituxan
Flag link:
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Yahoo/Reuters
Roche
Novartis
Italy
Avastin
Lucentis
marketing manipulation
Flag link:
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
Bloomberg
FDA
Avastin
biosimilars
Roche
Flag link:
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
Endpoints
FDA
Scott Gottlieb
Amgen
Allergan
biosimilars
Mvasi
Roche
Avastin
Flag link:
Key FDA Regulatory Events to Watch Out for in Sep 2017
Key FDA Regulatory Events to Watch Out for in Sep 2017
Yahoo/Zacks.com
FDA
Mylan Labs
Herceptin
biosimilars
trastuzumab
Shingrix
GSK
Pfizer
Sutent
PTC Therapeutics
Translarna
Amgen
Allergan
Avastin
Flag link:
Poor test results for Roche cloud growth prospects
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Amid sales growth, Roche plans defense from biosimilar threats
Amid sales growth, Roche plans defense from biosimilar threats
BioPharma Dive
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:

Pages